Capture Vascular is guided by directors who have achieved success in a variety of different fields including medical, providing seasoned and sound business perspectives and insights for the advancement of the company.
Jack Springer is a 25-year veteran of healthcare industry with global experience in general management, sales, and marketing for medical devices and diagnostics. He has a proven track record in strategic planning as well as sales and marketing execution. He provides guidance and expertise to both small and large companies to enable them to achieve their next stage of growth or overcome market and other challenges that their business may currently be facing.
Eric Wells is an experienced CEO, strategist, and investor with expertise in acquiring and managing companies. He resides on the boards of or is an advisor to companies in the medical device, real estate, tech and travel tech industries, and he has had a long and successful career developing commercial and residential real estate projects. Wells began his career as a builder, successfully completing a number of commercial and residential property developments.
In his work as an inventor and developer of medical and dental devices, Dr. Richard Fulton has sought to bring to market safe, easy-to-use and cost-effective devices and products designed to address a range of medical conditions and treatment dilemmas. In addition to the 40+ issued patents that Dr. Fulton has been awarded, he also has 60 pending patents and serves on the scientific advisory boards of several medical device companies. Fulton has numerous licensing agreements with companies prominent in the healthcare, pharmaceutical, and medical devices fields.
Jack Wolinetz is a healthcare industry consultant and has had a long and distinguished career working in the healthcare industry. He began with the Great American Insurance Company in 1964 before joining Pfizer in 1966. In 1975, Wollinetz moved to Bristol-Myers Squibb, rising to the position of president of Bristol Meyers Squibb China. He retired from Bristol-Myers Squibb in 1998.